Incyte Corporation INCY

Company Overview

Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of proprietary therapeutics, primarily in oncology and inflammation and autoimmunity. The company’s core competency is small-molecule drug discovery, with a strong emphasis on kinase inhibition and immune modulation. Incyte generates revenue primarily through product sales in the United States and royalties and milestone payments from strategic collaboration partners outside the U.S.

The company’s principal revenue drivers include Jakafi (ruxolitinib) for myeloproliferative neoplasms, Opzelura (ruxolitinib cream) for dermatologic inflammatory conditions, Pemazyre (pemigatinib) for cholangiocarcinoma, and Zynyz (retifanlimab) for certain oncology indications. Founded in 1991, Incyte initially focused on genomics-based drug discovery and later transitioned into a fully integrated biopharmaceutical company with commercial-stage assets, evolving through internal R&D and selective acquisitions.